Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levetiracetam bridging study in Korean adults with partial epilepsy
NCT00160628Phase 3
Key facts
- Status
- Completed
- Start
- Mar 2004
- Primary completion
- Oct 2004
- Sponsor
- UCB
- Modality
- Small Molecules
- Drugs
- levetiracetam
- Conditions
- partial epilepsy
01
Overview
Phase 3, open-label, single-arm trial of levetiracetam in partial epilepsy, sponsored by UCB. Primary endpoint: Seizure frequency per week at 16 weeks. Started Mar 2004; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Levetiracetam
Levetiracetam adjunctive therapy
03
Endpoints
Primary
Seizure frequency per week
Secondary
Adverse Events
Responder rate (>=50% reduction)
Seizure freedom rate
Beyond the preview
Go deeper on NCT00160628.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00160628.